 BROOKLYN, N.Y., June 08, 2021 GLOBE NEWSWIRE -- Brooklyn ImmunoTherapeutics, Inc. NYSE American: BTX Brooklyn, a biopharmaceutical company focused on exploring the role that cytokine and gene editingcell therapy can have in treating patients with cancer, blood disorders, and monogenic disorders, today announced the appointment of Kevin A. DAmour, Ph.D. as its Chief Scientific Officer. 